Abbott Laboratories Stock Underperforms Tuesday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Abbott Laboratories (ABT) shares fell 1.96% to $99.67 on Tuesday, underperforming the broader market and key competitors like Johnson & Johnson, Pfizer, and Merck. This decline ended a four-day winning streak. The stock remains 27.51% below its 52-week high of $137.49. Trading volume was lower than the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Abbott Laboratories (ABT) shed 1.96% to $99.67 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.89% to 7,509.20 and the Dow Jones Industrial Average rising 0.74% to 52,224.64.
The stock's fall snapped a four-day winning streak.
Abbott Laboratories closed 27.51% short of its 52-week high of $137.49, which the company reached on September 22nd.
The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 0.72% to $250.61, Pfizer Inc. (PFE) rose 0.77% to $24.94, and Merck & Co. Inc. (MRK) rose 1.50% to $126.26.
Trading volume (10.3 M) remained 3.2 million below its 50-day average volume of 13.5 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 21, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-21-26 1634ET